|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
ProMetic Life Sciences Inc. (PFSCF.PK): Lancet Study Reports 'Significant Breakthrough' In Quest To Prevent vCJD Transmission Through Blood Tranfusion
12/22/2006 11:30:52 AM
CAMBRIDGE, UNITED KINGDOM AND LILLE, FRANCE -- (MARKET WIRE) -- December 21, 2006 -- Pathogen Removal and Diagnostic Technologies Inc. (PRDT), a joint-venture between ProMetic Life Sciences Inc. (TSX: PLI) ("ProMetic") and The American Red Cross (ARC), along with PRDT's co-development, commercial and manufacturing partner, MacoPharma, announce that a study published today in the Lancet (Gregori L, Gurgel P, Lathrop J et al) reveals that PRDT's prion capture affinity resin incorporated into the P-CAPT® prion capture filter removes, to the limit of detection, the infectivity that is naturally present in blood during infections by Transmissible Spongiform Encephalopathies (TSE's), such as variant Creutzfeldt-Jakob disease (vCJD) and that it prevents the transmission of infection by contaminated blood.
|
|
|
|
|
|
|
|
|
|
|